Chronic oral anticoagulation frequently requires interruption for various reasons and durations. Whether or not to bridge with heparin or other anticoagulants is a common clinical dilemma. The evidence to inform decision making is limited, making current guidelines equivocal and imprecise. Moreover, indications for anticoagulation interruption may be unclear. New observational studies and a recent large randomized trial have noted significant perioperative or periprocedural bleeding rates without reduction in thromboembolism when bridging is employed. Such bleeding may also increase morbidity and mortality. In light of these findings, physician preferences for routine bridging anticoagulation 
M ore than 35 million prescriptions for oral anticoagulation (OAC) are written each year in the United States (1) . Conditions being treated with OAC include atrial fibrillation, mechanical heart valves, venous or arterial thromboembolism, and ventricular assist devices. In any given year, 15% to 20% of these patients will undergo an invasive procedure or surgery that interrupts their chronic OAC, putting them at increased risk for thromboembolism (TE), hemorrhage, and death (2, 3) . Perioperative or periprocedural (hereafter combined simply as periprocedural) anticoagulation management is a common clinical dilemma, often leading to significant adverse events. The clinical relevance of this common dilemma and the lack of definitive evidence to guide medical decision making has finally led to the conduct of pertinent clinical trials, 1 of which has been recently completed (4) . However, current guidelines from the American Heart Association, American College of Cardiology, Heart Rhythm Society, and American College of Chest Physicians have yet to incorporate the findings of this trial and remain based upon observational studies and expert opinion (5, 6 ). Yet, the guidelines do largely agree upon 3 important principles:
1. OAC should not be interrupted for procedures with low bleeding risk.
2. Patients at highest risk for TE without excessive bleeding risk should consider bridging. Conversely, those at low risk for TE should not be bridged.
3. Intermediate-risk cases ( Table 1) should be managed by individually considering patient-and procedure-specific risks for bleeding and TE.
Patients at low risk for TE should not create a clinical dilemma. Yet, physician surveys of periprocedural bridging preferences demonstrate that approximately 30% of physicians choose to bridge patients at low risk for TE due to overestimation of thrombosis risk (7) (8) (9) . There is even greater heterogeneity of practice in those patients with intermediate or unclear risks of bleeding or TE. Current evidence, including the recently completed BRIDGE
trial (Bridging Anticoagulation in Patients Who
Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery) (see later discussion), suggests that periprocedural bleeding rates are significantly higher than thrombosis rates in this group (2, 4, (10) (11) (12) (13) (14) (15) (16) .
The goal of this review is not to detail the timing, doses, or specifics of bridging anticoagulation. Rather, we will review the data available to specific questions that arise in clinical practice to better individualize decision making and reduce adverse events. We have limited the scope of the discussion to anticoagulant management. The periprocedural management of antiplatelet agents has been reviewed elsewhere (5, 17) .
CONFIRMING OAC INDICATIONS
When determining the optimal periprocedural anticoagulation strategy, a critical first step is to fully appreciate the indication for chronic OAC. In some cases, OAC may no longer be required. For example, a patient may present for a procedure who has been on warfarin for a single provoked deep vein thrombosis that occurred more than 6 months prior. In such a situation, discontinuation of OAC is most appropriate and will simplify periprocedural anticoagulation management.
In some cases, OAC is indicated for acute treatment of an existing or recent TE (i.e., in the past 3 to 6 months). Although temporary discontinuation of primary prevention OAC may be appropriate, treatment of an active thrombus should not be interrupted if at all possible. Unless a high bleeding-risk surgery is urgently needed, it is best to postpone the procedure until TE risk is attenuated.
AVOID OAC INTERRUPTIONS
Periprocedural warfarin interruption remains a routine practice for many clinicians. Recent data suggest that 40% to 60% of OAC interruptions may be unnecessary (2, 12, 18) . A 2005 survey of dermatologic surgeons revealed that 44% of them routinely interrupt OAC for dermatologic surgery-a procedure with low bleeding risk (19) . Other surveys similarly reveal that 90% to 100% of physicians would interrupt OAC and even bridge patients who are undergoing low bleeding-risk procedures regardless of TE risk (7, 18) .
OAC should not be interrupted for patients undergoing low bleeding-risk procedures, particularly those at high risk for TE. Uninterrupted warfarin throughout the periprocedural period is not associated with elevated bleeding risk for many procedures and surgeries, especially when a lower international normalized ratio (INR) goal of 2.0 is targeted (Table 2) (11, 16, 18, (20) (21) (22) (23) (24) (25) . Ironically, continuous warfarin therapy can paradoxically reduce periprocedural bleeding relative to interrupted warfarin with heparin bridging (20) .
Moreover, warfarin interruption and reinitiation can be associated with an increased incidence of stroke. In 1 retrospective study, warfarin initiation more than doubled the stroke risk during the first week compared with nonanticoagulated, matched control subjects (26, 27) . This paradox may be due to early depletion of the vitamin K-dependent factors, proteins C and S, creating a hypercoagulable milieu. Rechenmacher and Fang
Bridging Anticoagulation S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 9 2 -4 0 3 than one-third of these patients were not bridged. Of note, 20% of these patients experienced a major bleeding event.
Regarding venous thromboembolism (VTE), a recent observational study of 1,257 patients found only 6 recurrent VTE events (0.4%) during the periprocedural period (12) . Of the 236 patients at moderate to high risk of recurrent VTE, there was only 1 event. Two-thirds of these patients were not bridged.
No difference in recurrent VTE was detected between the bridged and nonbridged groups. Bleeding is increasingly recognized as a marker of 
Bridging Anticoagulation poor outcomes (33, 34 (40) . It is worth noting that the length of time warfarin is interrupted for a procedure is typically <5 days (13). Although it is not common practice to bridge subtherapeutic patients in the outpatient setting, many clinicians default to bridging during these short periprocedural periods-ironically, a time when patients are at greater risk of bleeding.
The threshold for bridging in current clinical practice is too low (8) . Moderate-and even low-risk patients are often being bridged by default, "just to be safe." Paradoxically, this practice is producing preventable adverse bleeding events with little benefit for thrombosis prevention. Clark et al. (12) recently described a large retrospective cohort of 1,812 procedures with chronic OAC interruption (12).
They found that 73% of patients bridged for VTE were at low risk for recurrence. In addition, they may not have required OAC interruption in the first place,
given that 39% of those procedures are similar to those listed in Table 2 . Bridging Anticoagulation S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 9 2 -4 0 3 adjusted odds ratio: 3.84; p < 0.0001) with no significant difference in TE events (2) .
THE BRIDGE TRIAL
In support of the mounting observational data, the recently published landmark BRIDGE trial now provides the most compelling evidence that routine bridging in moderate-risk patients is harmful. In the BRIDGE trial-a randomized, double-blinded, placebocontrolled noninferiority study-1,884 atrial fibrillation patients (valvular and nonvalvular) who were undergoing a procedure with planned warfarin interruption were randomized to anticoagulation bridging with the low molecular-weight heparin, dalteparin, or placebo (4). The reasons for OAC interruption were not specified, but importantly, Rechenmacher and Fang Figures 3C and 3D ).
Candidates for uninterrupted OAC are those patients at moderate or high risk for TE and who are undergoing a reasonably low bleeding risk procedure ( Table 2) . To avoid unnecessary bleeding with uninterrupted OAC, also consider a lower periprocedural INR goal of 2.0 ( Figure 3D ).
If OAC interruption is necessary, avoid bridging patients ( Figure 3A) at low or moderate risk for TE Conveniently, higher BleedMAP scores also correlate with lower TE rates ( Figure 4) .
The net clinical benefit of bridging patients at "high risk" for TE ( When bridging is deemed necessary, more conservative bridging strategies should be entertained, such as low-dose heparin ( Figure 3F ) ( 
